← Back to patent-cliff list
阿莫西林/奥美拉唑/利福布汀
Tier C — Watch / tradeAmoxicillin/Omeprazole/Rifabutin
Redhill Biopharma Inc
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
天然产物/提取物
Type
Targets：Proton pump、RNAP、PBPs
Brand：Talicia
Indications (approved)：幽门螺杆菌感染
Regional status
US
批准上市
2019-11-01
EU
-
China
临床申请
2025-12-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amoxicillin/Omeprazole/Rifabutin?
Approved indications include: 幽门螺杆菌感染.
When does the Amoxicillin/Omeprazole/Rifabutin patent expire?
No public expiry year is available for Amoxicillin/Omeprazole/Rifabutin yet; this page updates once verified.
How do I get a quote for Amoxicillin/Omeprazole/Rifabutin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24